Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹923.80down ₹22.20 (2.35%)BSE ₹924.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.
30 Oct: open ₹946.00, high ₹951.80, low ₹920.00
52-week range of traded prices to 30 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,714 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 35.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.54%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,22937.1% delivered
Jubilant Pharmova share news and announcements
1,152 announcements, routine notices left out, newest first. Page 22 of 24.
Apr 2009
20 Apr · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2009. (2) Recommendation of Dividend for the year ended March 31, 2009.9 Apr · Business
Press release dated April 09, 2009, titled "Jubilant and Orion ink "Hybrid and Integrated" Drug Discovery Collaboration". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
30 Mar · Foreign Currency Convertible Bonds
Company has bought back part of the Foreign Currency Convertible Bonds due 2011, amounting to US$ 1,500,000 at a discount, in compliance with RBI regulations and the same have been cancelled on March 27, 2009.12 Mar · Business
Press release dated March 11, 2009, titled "DRAXIMAGE, a Jubilant Organosys Company signs an agreement with Guerbet to distribute its nuclear medicine products in Europe". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Business
Press release dated March 02, 2009, titled "Jubilant Receives Approvals for Sestamibi in Canada ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2009
26 Feb · Business
"Further to our announcement dated February 10, 2009, February 19, 2009 and February 23, 2009, we wish to announce that, as advised by our Banker, all the Bonds accepted by the Company for repurchase, have been cancelled as per details below: (a) 3,000 Bonds due in 2010 of the aggregating principal amount of US$ 3.000 million; (b) 453 Bonds due in 2011 of the aggregating principal amount of US$ 45.300 million; The aggregate principal amount outstanding after cancellation of the repurchased Bonds is: (a) 49,657 Bonds due in 2010- outstanding principal amount of US$ 49.657 million; (b) 1,436 Bonds due in 2011- outstanding principal amount of US$ 143.600 million." A copy of the Press Release dated February 25, 2009 titled "Jubilant buys back FCCBs worth USD 59 million- Records cumulative gain of USD 25 million" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Feb · Updates
Notice of Settlement - Tender Offer for repurchase of FCCBs due in 2010 and 2011. The details of the shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Feb · Updates
Final Allocation Notice - Tender Offer for repurchase of FCCBs due in 2010 and 2011. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Feb · Updates
Jubilant Organosys Limited (the "Company") has issued Convertible Bonds of US$ 75,000,000 (current outstanding US$ 52,657,000) and US$ 200,000,000 (current outstanding US$ 188,900,000) due in 2010 and 2011 respectively. The Company intends to repurchase for cash an aggregate principle amount of the outstanding Bonds in an amount to be determined by the Company at its sole discretion, by way of an invitation to holders of Bonds to tender their Bonds for repurchase. The Company proposes to dispatch to Bondholders a Tender Offer Memorandum dated February 10, 2009 setting out, inter alia, the terms and conditions of the Invitation to Tender. The Invitation to Tender will commence on February 11, 2009 and will expire on February 12, 2009, unless extended, re-opened or earlier terminated as provided in the Tender Offer Memorandum.6 Feb · Disclosure
As per Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997, the promoters and promoter group hold 50.41% of the Company's capital, out of which 13.66% is pledged. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Feb · Foreign Currency Convertible Bonds
Company has bought back part of the Foreign Currency Convertible Bonds due 2011, amounting to US $ 11,100,000 at a discount, in compliance with RBI regulations and the same have been cancelled on February 05, 2009.
Jan 2009
27 Jan · Business
Press release dated January 27, 2009, titled "Q3 FY09 Revenues up 42% to Rs. 910 crore; 9M FY09 Revenues up 49% to Rs. 2,677 crore; 9M FY09 EBITDA up 46% to Rs. 512 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 90964 lacs for quarter ending on 31-DEC-2008 against Rs. 64160 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (8757) lacs for the quarter ending on 31-DEC-2008 against Rs. 8870 lacs for the quarter ending on 31-DEC-2007.27 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 58741 lacs for quarter ending on 31-DEC-2008 against Rs. 49450 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (2116) lacs for the quarter ending on 31-DEC-2008 against Rs. 8510 lacs for the quarter ending on 31-DEC-2007.21 Jan · Business
Press release dated January 21, 2009, titled "Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jan · Board meeting
Meeting on 27 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”13 Jan · Business
Press release dated January 13, 2009, titled "Jubilant and BioLeap announce new partnership in Drug Discovery". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
24 Dec · Foreign Currency Convertible Bonds
Pursuant to the RBI circular dated December 08, 2008 on buy back of Foreign Currency Convertible Bonds (FCCBs), the Board of Directors of the Company have resolved to explore/ effect opportunities for buying back of FCCBs issued by the Company and outstanding as on date, subject to applicable laws and necessary regulatory approvals/ filings and subject to availability of funds.
Nov 2008
28 Nov · Results
Based on the Postal Ballot forms received from shareholders and as per the Scrutinizer's Report dated November 25, 2008, the following six resolutions have been declared passed with requisite majority through postal ballot: - (1) Special resolution for modification of Jubilant Employees Stock Option Plan 2005. (2) Special resolution for Constitution of Jubilant Employees Welfare Trust. (3) Special Resolution for Re-appointment of Mr. S.N. Singh as Executive Director. (4) Ordinary Resolution for Re-appointment of Mr. Shyamsundar Bang as Executive Director. (5) Ordinary Resolution for increase in Borrowing Limits. (6) Ordinary Resolution granting Authority to create Charge on Company's assets. The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Nov · Demise of Director
Mr. Bodhishwar Rai ceased to be the Director with effect from October 16, 2008, due to sudden demise.17 Nov · Business
Press release dated November 17, 2008, titled "Jubilant augments Clinsys Clinical Research (R) through acquisition of TrialStat ClinicalAnalytics (R), an EDC platform". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
29 Oct · Business
Press release dated October 29, 2008, titled "Jubilant Strengthens its Business Model in North America - Strategically Aligns HollisterStier and Draxis-Announces New Leadership". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Oct · Meeting
As per Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolutions by Postal Ballot) Rules, 2001, the Company may seek the approval of its shareholders to any resolutions through Postal Ballot: (1) Modification of Jubilant Employees Stock Option Plan 2005. (2) Constitution of Jubilant Employees Welfare Trust. (3) Re-appointment of Mr. S. N. Singh as Executive Director. (4) Re-appointment of Mr. Shyamsundar Bang as Executive Director. (5) Increase in Borrowings Limits. (6) Authority to create Charge on Company's Assets. The Board of Directors has appointed Mr.Sanjay Grover, Practising Company Secretary as scrutinizer for conducting the postal ballot process in a fair and transparent manner. The duly completed Postal Ballot Form should reach the Scrutinizer on or before November 24, 2008. The Scrutinizer will submit his report to the Chairman after completion of the scrutiny of the Postal ballot Forms and the results of Postal Ballot will be announced on November 26, 2008. A copy of the Notice of the Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Oct · Allotment of shares/ others
At a Meeting of the Compensation Committee of the Board of Directors held today i.e. October 14, 2008, allotment of 12860 equity shares of Re.1/- each at a price of Rs.201.33 per share has been made pursuant to exercise of 2572 options earlier granted under the "Jubilant Employees Stock Option Plan 2005." Further 5,600 Options have been granted to eligible employees of the Company on October 14, 2008 in accordance with Jubilant Employees Stock Option Plan, 2005. Each option shall entitle the holder to subscribe to 5 equity shares of Re.1 each at a price of Rs.198.55 per share.14 Oct · Management
A) Mr. Ajay Relan has ceased to be Director of the Company. Further Mr. Vishal Marwaha has ceased to be Alternate Director to Mr. Ajay Relan. b) Mr. Rahul Yadav has been appointed as Additional Director on the Board of Directors of the Company with effect from October 14, 2008. Further Mr. Vishal Marwaha has been appointed as Alternate Director to Mr. Rahul Yadav with effect from October 14, 2008. c) The Board of Directors have decided to increase the number of Employee Stock Options from existing 7,17,500 options (giving right to acquire upto 35,87,500 equity shares of Re.1/- each) to 11,00,000 options (giving right to acquire upto 55,00,000 equity shares of Re.1/- each), subject to members approval, to be granted to eligible employees either by way of subscription to fresh shares or through trust route.14 Oct · Results
Standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 129525 lacs for half year ending on 30-SEP-2008 against Rs. 94790 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (988) lacs for the half year ending on 30-SEP-2008 against Rs. 25010 lacs for the half year ending on 30-SEP-2007.14 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 67900 lacs for quarter ending on 30-SEP-2008 against Rs. 49300 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (2439) lacs for the quarter ending on 30-SEP-2008 against Rs. 11170 lacs for the quarter ending on 30-SEP-2007.14 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 176710 lacs for half year ending on 30-SEP-2008 against Rs. 115830 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (4996) lacs for the half year ending on 30-SEP-2008 against Rs. 24930 lacs for the half year ending on 30-SEP-2007.14 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 94050 lacs for quarter ending on 30-SEP-2008 against Rs. 61830 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (6272) lacs for the quarter ending on 30-SEP-2008 against Rs. 10960 lacs for the quarter ending on 30-SEP-2007.14 Oct · Business
Press release dated October 14, 2008, titled "Q2 FY09 Revenues up 52% to Rs. 941 crore; Q2 FY09 EBITDA up 56% to Rs. 184 crore; H1 FY09 Revenues up 53% to Rs. 1,767 crore; H1 FY09 EBITDA up 64% to Rs. 355 crore; Expects to post more than 50% increase in Revenues for FY2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Oct · Board meeting
To inter-alia consider and take on record the Unaudited Financial Results of the Company for the quarter ended September 30, 2008.3 Oct · Business
Press release dated October 03, 2008, titled "Jubilant Organosys and Lilly to Form Drug Development Joint Venture". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
30 Sep · Meeting
Proceedings of the Annual General Meeting of the Company held on September 27, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Sep · Meeting
Annual General Meeting of the Company will be held on September 27, 2008 and the Register of Members/Share Transfer Books of the Company will remain closed from September 19, 2008 to September 27, 2008, both days inclusive, for the purpose of Annual General Meeting and Dividend.
Jul 2008
15 Jul · Business
Press release dated July 15, 2008, titled "Q1 FY09 Revenues up 53% to Rs.826.6 crore; Pharma & Life Sciences Revenues increase 72%; Q1 FY09 EBITDA increases 62% to Rs.173.2 crore; Expects to post more than 50% Increase in Revenues for FY2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 82660 lacs for quarter ending on 30-JUN-2008 against Rs. 54000 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 1276 lacs for the quarter ending on 30-JUN-2008 against Rs. 14290 lacs for the quarter ending on 30-JUN-2007.15 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 61625 lacs for quarter ending on 30-JUN-2008 against Rs. 45490 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 1451 lacs for the quarter ending on 30-JUN-2008 against Rs. 13840 lacs for the quarter ending on 30-JUN-2007.15 Jul · Allotment of Equity Shares
At a Meeting of the Compensation Committee of the Board of Directors held on July 15, 2008, allotment of 30,020 equity shares of Re.1/- each at a price of: Rs.201.33 per share for 29,120 equity shares and Rs.258.25 per share for 900 equity shares, has been made pursuant to exercise of 6004 options earlier granted under the "Jubilant Employees Stock Option Plan 2005". Further, 8,000 Options have been granted to eligible employees of the Company on July 15, 2008 in accordance with Jubilant Employees Stock Option Plan, 2005. Each option shall entitle the holder to subscribe to 5 equity shares of Re.1 each at a price of Rs.304.95 per share.14 Jul · Business
Press release dated July 14, 2008, titled "Jubilant in Drug Discovery partnership with Amgen Inc, USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Jul · Board meeting
Meeting on 15 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”4 Jul · Results
Based on the Postal Ballot forms received from shareholders and as per the Scrutinizer's Report dated July 02, 2008, the following special Resolution (as per attachment) have been declared passed with requisite majority. A summary of the votes received on these resolution and the details of the resolutions shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2008
30 Jun · Allotment of shares
At a Meeting of the Special Committee of the Board of Directors held on June 30, 2008, allotment of 79,376 equity shares of Re.1/- each at a premium of Rs.272.0648 per share has been made to Swiss Finance Corp.(Mauritius) Ltd., on conversion of a part of the Foreign Currency Convertible Bonds amounting to US $ 0.5 Million.3 Jun · Meeting
As per Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolutions by Postal Ballot) Rules, 2001, the Company may seek the approval of its shareholders to any resolutions through Postal Ballot: (1) Modification of the Jubilant Employees Stock Option Plan 2005 to provide for accelerated vesting and new Lock-in provisions, etc. (2) Modification of the Jubilant Employees Stock Option Plan 2005 to provide for recovery of Fringe Benefit Tax, etc. The Board of Directors has appointed Mr.Sanjay Grover, Practising Company Secretary as scrutinizer for conducting the postal ballot process in a fair and transparent manner. The duly completed Postal Ballot Form should reach the Scrutinizer on or before June 30, 2008. The Scrutinizer will submit his report to the Chairman after completion of the scrutiny of the Postal ballot Forms and the results of Postal Ballot will be announced on July 04, 2008. A copy of the Notice of the Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jun · Allotment of shares
At a Meeting of the Special Committee of the Board of Directors held on June 02, 2008, allotment of 10,31,897 equity shares of Re.1/- each at a premium of Rs.272.0648 per share has been made to Grants Investments Ltd., on conversion of a part of the Foreign Currency Convertible Bonds amounting to US $ 6.5 Million.
May 2008
29 May · Business
Press release dated May 28, 2008, titled "Jubilant successfully completes acquisition of Draxis for US$ 253 million". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 May · Business
Press release dated May 08, 2008, titled "Jubilant acquires Speciality Molecules Pvt Ltd., India; Acquisition to further strengthen company's Pyridine portfolio". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 May · Allotment of Equity Shares
At a Meeting of the Special Committee of the Board of Directors held today i.e. May 05, 2008, allotment of 198,441 equity shares of Re.1/- each at a premium of Rs.272.0648 per share has been made to Swiss Finance Corp. (Mauritius) Limited and CQS Master Fund Limited on conversion of a part of the Foreign Currency Convertible Bonds amounting to US $ 1.250 Million
Apr 2008
24 Apr · Allotment of shares/ others
"At a Meeting of the Compensation Committee of the Board of Directors held today i.e. April 22, 2008, allotment of 3,750 equity shares of Re.1/- each at a price of Rs.201.33 per share, has been made pursuant to exercise of 750 options earlier granted under the "Jubilant Employees Stock Option Plan 2005". Further, 9,100 Options have been granted to eligible employees of the Company on April 22, 2008 in accordance with Jubilant Employees Stock Option Plan, 2005. Each option shall entitle the holder to subscribe to 5 equity shares of Re.1 each at a price of Rs.359.25 per share.22 Apr · Updates
Particulars for the year ended March 31, 2008, in terms of Clause 20 of the Listing Agreement. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Apr · Business
Press release dated April 22, 2008, titled "Q4 FY08 Revenues grown 49% to Rs.6,890 million; Net Profit at Rs.582 million; Pharma & Life Science revenues increase 102%; FY08 Revenues improved 38% to Rs. 24,889 million, PAT up 76% at Rs. 4,005 million; Pharma & Life Science revenues increase 71%; Board declares increased dividend at 150% for the year". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.